Bristol-myers Squibb Compnay

Access Medical Systems, Ltd.

Indrani Chakraborty

Mohan Srinivasan

Alan J Korman

Guodong Chen

Mark J Selby

Haichun Huang

Nils Lonberg

Richard Y Huang

Changyu Wang

Karla Ann Henning

Michelle Minhua Han

Huiming Li

Susan Wong

Paul O Sheppard

Mark F Maurer

Thomas D Kempe

Xi-Tao Wang

Scott R Presnell

Mark W Rixon

Josephine M Cardarelli

Brigitte Devaux

Stanley Richard Krystek, Jr

Kent B Thudium

Alison Witte

Alexander T Kozhich

Daniel F Ardourel

Robert F Zuk

Arvind Rajpal

Maria N Jure-Kunkel

Han Chang

Brenda L Stevens

Jochem Gokemeijer

Tseng-hui Timothy Chen

Michael Quigley

Hui Wei

Aaron Paul Yamniuk

Bryan C Barnhart

Ming Lei

Steven Sheriff

Susan Chien-Szu Wong

Lumelle A Schneeweis

Xiang Shao

Susan H Julien

Hadia Lemar

Zhehong Cai

Marie-Michelle Navarro Garcia

Christina Maria Milburn

Patrick Guirnalda

Olufemi A Adelakun

Anne C Lewin

Sandra V Hatcher

Liang Schweizer

Pu Li

Thomas Edwards

Praveen Aanur

Zheng Yang

Jackie Shek Kei Chan

Kateri Atkins

Noah Ditto

Susan C Wong

Tracy Arakaki

Nels B Hamacher

Christine Huang

Yan Feng

Maria Rodriguez

Stanley R Krystek

Mian Gao

The present invention is directed to biochemical assay methods, which re-use a hapten-immobilized test probe and reagents for quantitating an analyte or measuring kinetic binding in different samples, anywhere from about 3 to 20 times, while maintaining acceptable assay performance. The methods use a conjugate solution either comprising (i) an anti-hapten antibody and a capture antibody against an analyte, or (ii) an anti-hapten antibody and streptavidin, in each cycle and regenerate the hapten-coated test probe by dipping the test probe in an acidic solution having pH about 1-4, optionally further dipping in a DMSO solution, after the completion of each cycle of reaction. The robustness of the hapten-immobilized solid phase allows utilization of denaturation reagents for efficient elution of the immune complexes after each cycle without compromising the binding activity of the hapten on the solid phase.

Method for re-using test probe and reagents in biochemical assay based on interferometry

The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.

Antibodies to TIGIT

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against OX-40 and uses thereof

Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.

Anti-GITR antibodies for cancer diagnostics

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)

Antibodies against OX40 and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.

Methods of treating inflammation with IL-17A/F and IL-23P19 bispecific antibodies

Polynucleotides encoding IL-17/IL-23 bispecific, IL-17A/F and IL-23p19 antibodies

Growing community of inventors

Fremont, CA, United States of America

Indrani Chakraborty